Navigation Links
Proportion of opioid treatment programs offering on-site testing for HIV and STIs declines
Date:12/24/2013

A survey of opioid treatment programs finds that the proportion offering on-site testing for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) declined substantially between 2000 and 2011, despite guidelines recommending routine opt-out HIV testing in all health care settings, according to a study appearing in the December 25 issue of JAMA.

"Opioid dependence is a risk factor for HIV, STIs, and hepatitis C virus (HCV) infection. Opioid treatment programs, which provide treatment to more than 300,000 opioid-dependent individuals in the United States, are well-positioned to offer testing for these infectious diseases to a high-risk population. They were among the first venues to offer HIV testing and are more likely to offer HIV, STI, and HCV testing than other drug treatment programs. Private for-profit opioid treatment programs are increasingly widespread and such programs offer on-site HIV testing less often than nonprofit and public programs. However, with the 2006 national recommendations for routine opt-out HIV testing, we hypothesized that the percentage of programs offering on-site testing for HIV, STIs, and HCV would increase," the authors write.

Marcus A. Bachhuber, M.D., and Chinazo O. Cunningham, M.D., M.S., of the Albert Einstein College of Medicine, New York, analyzed data from a survey sent to directors of drug treatment facilities and tabulated the percentage of opioid treatment programs offering on-site HIV, STI, and HCV testing from 2000 to 2011.

The number of U.S. opioid treatment programs increased from 849 in 2000 to 1,175 in 2011. The percentage of programs operating as for-profit businesses increased from 43 percent to 54 percent, nonprofits decreased from 43 percent to 36 percent, and public programs decreased from 14 percent to 10 percent. From 2000 to 2011, the absolute number of programs offering testing for HIV, STIs, and HCV increased but the percentage offering on-site testing for HIV declined by 18 percent and for STIs by 13 percent. There was no change for HCV testing. More than 75 percent of public programs offered on-site testing for each infection, with no change over time.

"Declines were most pronounced in for-profit programs, suggesting that persons enrolled in these programs may be at increased risk for delayed diagnosis and continued transmission of HIV, STIs, and HCV," the authors write.

"Opioid treatment programs are important venues for offering testing to high-risk individuals. As the number of for-profit opioid treatment programs increases, and the opioid, HIV, and HCV epidemics continue to intersect, further work is needed to understand and reverse declines in offering on-site testing."


'/>"/>

Contact: Kim Newman
Sciencenews@einstein.yu.edu
718-430-3101
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Infections cause lower proportion of lead extractions than expected
2. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
3. Eye and Vision Diseases are at Epidemic Proportions
4. Pacific Island Public Health Group Declares Diabetes at Pandemic Proportions
5. Higher proportion of California children uninsured than in US, USC analysis shows
6. Cigarette Taxes Disproportionately Burden the Poor, Report Says
7. Elder abuse affects Latinos disproportionately
8. VitaPro Labs Launches New Withdrawal Aid System at WithdrawalAid.com, a Supplement Proven To Ease Opioid Withdrawal Symptoms
9. Prescription opioid abusers prefer to get high on oxycodone and hydrocodone
10. Modern Medical’s Opioid Defense Manager Sees Measureable Results in Just 12 Months.
11. Avoiding Addiction When Powerful Opioid Painkillers Are Needed, From the November 2013 Harvard Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... In its just released 2018 ... and Harry Nelson. This is the third consecutive year that Hardiman and Mills have ... were both recognized for expertise in Health Care Law while Mills was recognized in ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on NextShark ... surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop and ... standards of male appearance are changing not only in the Asian nation, where plastic ...
(Date:8/17/2017)... ... 17, 2017 , ... Inc. Magazine Unveils 36th Annual List of America’s Fastest-Growing ... Growth of 3,004.8% , NEW YORK, August 16, 2017 – Inc. magazine today ranked ... of the nation's fastest-growing private companies. The list represents a unique look at the ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Summer days ... Island’s original family-owned supermarket, has put together suggestions for enjoying the season of sunshine. ... or activity, everyone in the family can join in on the fun. , ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... Aug. 1, 2017   CerSci Therapeutics , a ... Texas , has received notice from the National ... of Health (NIH) that it has been awarded a ... over $650,000 in 2017 with an additional $1,000,000 to ... New Drug application of their lead non-opioid drug candidate ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
(Date:7/26/2017)... BEACH, Fla. , July 26, 2017 ... of enrollment of our clinical trial evaluating Altemia TM ... Cell Anemia (SCA) and Sickle Cell Disease (SCD). The ... to evaluate the efficacy and safety of Altemia TM ... trial is conducted under US IND 125274. ...
Breaking Medicine Technology: